Skip to content

To compare the efficacy and safety of two different analgesic formulations in the management of pain following tooth extraction.

A randomized open label comparative study evaluating the efficacy and tolerability of diclofenac (50 mg) + paracetamol (500 mg) FDC vs. paracetamol 500 mg in the management of dental pain following tooth extraction

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2010/091/000099
Enrollment
50
Registered
2010-02-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Dental pain following tooth extraction

Interventions

Intervention1: Fixed Dose of Diclofenac 50 mg + Paracetamol 500 mg: one tablet Twice a Day Control Intervention1: Paracetamol 500 mg: One tablet Four times a Day

Sponsors

Troikaa Pharmaceuticals Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients undergoing tooth extraction under local anesthesia. 2.Between the ages of 16 to 35 years 3.Willing to undergo observation period for four hours post-extraction 4.Willing for telephonic follow up and at least 1 follow up visit. 5.Ability to complete a 10 cm visual analog scale and a category scale every 30 minutes for the first 4 post extraction hours

Exclusion criteria

Exclusion criteria: 1.Surgical Time in excess of 45 minutes 2.Patients with known hypersensitivity to any of the study drugs 3.Patients with any contraindications to the study drugs 4.Patients who are pregnant or nursing 5.Patients with history of peptic ulcers and/or GI bleeding 6.Patients who have significant psychiatric history 7.Patients with severe kidney/ liver disease 8.Patients who are taking any of the following drugs: ACE inhibitor; potassium sparing diuretics; aspirin on a near daily basis; warfarin or other anti- coagulants 9.Unusual surgical difficulty (determined from panoramic radiograph or during the actual surgery) 10.Patients who have received treatment with any nonmarketed drug substance (i.e. an agent which has not yet been made available for clinical use) within 4 weeks prior to randomisation; 11. Patient known or, in the opinion of the investigator, is unlikely to comply with the Clinical Study Protocol (e.g. alcoholism, drug dependency, or psychotic state).

Design outcomes

Primary

MeasureTime frame
Time to onset of analgesia, Time to Maximum Pain relief (tMaxPR), Pain relief at 8 hrs (PR8)Timepoint: After administration of study medication

Secondary

MeasureTime frame
Pain intensity difference at 8 hours (PID8); Pain relief scores; Rescue analgesia requirement; Global efficacy by patients and investigator. Timepoint: At 8 hours after study medication adminstartion; At 30, 60 minutes, 2, 4, 6, 8, 24, 48 hrs of giving the medication and on the 4th post extraction day; At 8, 48 hours and 4th post extraction day; At the end of study.

Countries

India

Contacts

Public ContactDr Vijaya Jaiswal

Troikaa Pharmaceuticals Limited

vijayajaiswal@troikaapharma.com079-26856242

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026